Table 2. Completed clinical trials with proteasome inhibitors and other drugs.
| Compound | Sponsor | Combination | Condition | Phase | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
| Marizomib/Salinosporamide A/NPI-0052 | Triphase Research and Development I Corporation | Vorinostat | Non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma | Phase 1, completed | NCT00667082 |
| - | Advanced malignancies | Phase 1, completed | NCT00629473 | ||
| - | Advanced solid tumor Malignancies or refractory lymphoma | Phase 1, completed | NCT00396864 | ||
| Oprozomib/ONX0912 | Onyx Therapeutics, Inc. | - | Advanced refractory or recurrent solid tumors | Phase 1, completed | NCT01129349 |
| Ixazomib/MLN-9708 | Millennium Pharmaceuticals, Inc. | - | Advanced nonhematologic malignancies | Phase 1, completed | NCT00830869 |
| - | Relapsed and/or refractory multiple myeloma | Phase 1, completed | NCT00932698 | ||
| - | Relapsed and refractory multiple myeloma | Phase 1, completed | NCT00963820 | ||
| Lenalidomide Dexamethasone | Newly diagnosed multiple myeloma | Phase 1 Phase 2, completed | NCT01217957 | ||
| Delanzomib/CEP-18770 | Cephalon | - | Solid tumours or non-hodgkin's lymphomas | Phase 1, completed | NCT00572637 |
| Lenalidomide Dexamethasone | Relapsed or refractory multiple myeloma | Phase 1 Phase 2, terminated | NCT01348919 | ||
| - | Relapsed multiple myeloma refractory to the most recent therapy | Phase 1 Phase 2, terminated | NCT01023880 |
Shown are the completed trials of anti-cancer therapies with proteasome inhibitors in combination with other drugs sponsored by various companies. Cancer conditions and accomplished phases are indicated.